p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates

PLoS One. 2016 Jan 5;11(1):e0146031. doi: 10.1371/journal.pone.0146031. eCollection 2016.

Abstract

The cell cycle inhibitor p21CDKN1A was previously found to interact directly with DNA nick-sensor poly(ADP-ribose) polymerase-1 (PARP-1) and to promote base excision repair (BER). However, the molecular mechanism responsible for this BER-related association of p21 with PARP-1 remains to be clarified. In this study we investigate the capability of p21 to influence PARP-1 binding to DNA repair intermediates in a reconstituted BER system in vitro. Using model photoreactive BER substrates containing single-strand breaks, we found that full-length recombinant GST-tagged p21 but not a C-terminal domain truncated form of p21 was able to stimulate the PARP-1 binding to BER intermediates with no significant influence on the catalytic activity of PARP-1. In addition, we investigate whether the activation of PARP-1 through poly(ADP-ribose) (PAR) synthesis, is required for its interaction with p21. We have found that in human fibroblasts and in HeLa cells treated with the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), the interaction of p21 with PARP-1 was greatly dependent on PAR synthesis. In fact, an anti-PAR antibody was able to co-immunoprecipitate p21 and PARP-1 from extracts of MNNG-treated cells, while blocking PAR synthesis with the PARP-1 inhibitor Olaparib, drastically reduced the amount of p21 co-immunoprecipitated by a PARP-1 antibody. Our results provide the first evidence that p21 can stimulate the binding of PARP-1 to DNA repair intermediates, and that this cooperation requires PAR synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Western
  • Cell Line
  • Chromatin / genetics
  • Chromatin / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism*
  • DNA Breaks, Single-Stranded*
  • DNA Repair*
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • HeLa Cells
  • Humans
  • Methylnitronitrosoguanidine / pharmacology
  • Microscopy, Fluorescence
  • Mutation
  • Phthalazines / pharmacology
  • Piperazines / pharmacology
  • Poly Adenosine Diphosphate Ribose / metabolism
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
  • Poly(ADP-ribose) Polymerases / genetics
  • Poly(ADP-ribose) Polymerases / metabolism*
  • Protein Binding

Substances

  • CDKN1A protein, human
  • Chromatin
  • Cyclin-Dependent Kinase Inhibitor p21
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Methylnitronitrosoguanidine
  • Poly Adenosine Diphosphate Ribose
  • Poly(ADP-ribose) Polymerases
  • olaparib

Grants and funding

This work was supported by Grant no. 5126 to EP, Associazione Italiana Ricerca sul Cancro (www.airc.it), and Grant no. 14-24-00038 to OIL, Russian Science Foundation (www.rscf.ru). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.